A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

A Phase 1, Single-center, Open-label, Fixed-sequence, Crossover Study to Evaluate the Effect of LY4100511 (DC-853) on the Single-dose Pharmacokinetics of Midazolam, Repaglinide, Digoxin, and Rosuvastatin in Healthy Participants

The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.

Inclusion Criteria:

• Females must be of childbearing potential
• Males must agree to use contraception
• Have body mass index (BMI) between 18.0 and 32.0 kilogram/square meter (kg/m²), inclusive, and a body weight of greater than or equal to 50 kg.
• In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clincial laboratory evaluations (congentical nonhemolytic hyperbilirubinemia) at screening and check-in, and from the physical examination at check-in as assessed by the investigator.

Exclusion Criteria:

• Have a 12-lead ECG abnormality that, in the opinion of the investigator,

  • increases the risks associated with participating in the study

  • may confound ECG data analysis

  • a QTCF >450 msec for males, or >470 msec for females

    • short PR interval <120 msec or PR interval >220 msec
    • second or third degree atrioventricular block
    • intraventricular conduction delay with QRS >120 msec
    • complete right bundle branch block
    • left bundle branch block, or
    • Wolff Parkinson-White syndrome.

• Have had current or recent acute infection

• Show evidence of active or latent tuberculosis (TB)

• Had any surgical procedures within 12 weeks prior to screening or any planned surgical procedure scheduled to occur during the study.

• Have a history or presence of multiple or severe allergies, or an anaphylactic reaction to prescription or non prescription drugs.

• Are immunocompromised

• Presence of active suicidal ideation or positive suicide behavior using baseline/screening version of the C-SSRS